# VERSATILE-003 (NCT06790966)

> Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06790966
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: PDS Biotechnology Corp.
- Conditions: Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Neoplasms, Head and Neck; Unresectable Head and Neck Squamous Cell Carcinoma
- Interventions: Combination Treatment of PDS0101 and Pembrolizumab; Pembrolizumab Monotherapy
- Enrollment: 12
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=versatile-003-nct06790966